Thursday, May 23, 2013 Last update: 7:34 PM
Company Tech News as it Breaks
Trade Events
Arrowhead Research Corporation
News articles for Arrowhead Research Corporation:
Thursday, May 9, 2013
- Arrowhead Reports Fiscal 2013 Second Quarter Financial ResultsArrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2013 second quarter ended March 31, 2013. The company is hosting a ... read more
Monday, May 6, 2013
- Arrowhead Closes $36 Million Private OfferingArrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that on May 3, 2013 it closed a previously announced private offering of common and convertible preferred ... read more
Monday, April 29, 2013
- Arrowhead Prices $36 Million Private OfferingArrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it has priced a private offering with gross proceeds expected to be $36 million. The offering ... read more
Wednesday, April 24, 2013
- Arrowhead to Present at Needham Healthcare ConferenceArrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that its COO and Head of R&D, Dr. Bruce Given, will present at the Needham Healthcare Conference ... read more
Monday, March 25, 2013
- Arrowhead Induces 90% Reduction in Hepatitis B Antigens in Chimpanzee with Chronic Infection: Data Follow Previous Report of Reduction in Viral DNAArrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, will host an analyst event today in New York City to discuss ARC-520, its RNAi-based candidate designed to treat ... read more
Thursday, March 14, 2013
- Arrowhead RNAi Candidate ARC-520 Induces Greater than 90% Reduction in Circulating HBV DNA in Chimpanzee with Chronic Hepatitis BArrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that a study of its RNAi-based candidate ARC-520 in a chimpanzee chronically infected with the human hepatitis ... read more
Thursday, March 7, 2013
- Arrowhead to Host Analyst Event in New York to Discuss RNAi-based Hepatitis B Candidate ARC-520Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it will host an analyst and investor event on Monday, March 25, from 12:30 to 2:00 ... read more
Thursday, February 28, 2013
- Arrowhead Receives Notice of Patent Allowance for New Protease Sensitive Masking Chemistry for DPC siRNA Delivery SystemArrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent ... read more
Tuesday, February 26, 2013
- Arrowhead Data Demonstrates RNAi Candidate ARC-520 Silences Hepatitis B VirusArrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced the publication of data demonstrating multi-log reductions in hepatitis B viral DNA and proteins lasting over 30 ... read more
Wednesday, February 13, 2013
- Arrowhead Reports Fiscal 2013 First Quarter Financial ResultsArrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2013 first quarter ended December 31, 2012. The company is hosting a ... read more
Wednesday, February 6, 2013
- Arrowhead to Report Fiscal 2013 First Quarter Financial ResultsArrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it will report its financial results for the fiscal 2013 first quarter ended December 31, 2012, ... read more
Friday, February 1, 2013
- Arrowhead to Present at Upcoming Scientific ConferencesArrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that academic collaborators and scientists from the company will present data on the Dynamic PolyConjugate™ (DPC) siRNA ... read more
Friday, January 25, 2013
- Arrowhead Announces Pricing of a Public Offering of Common Stock and WarrantsArrowhead Research Corporation (NASDAQ: ARWR) today announced that it has priced a public offering of approximately 1.65 million units at a price to the public of $2.12 per ... read more
Thursday, January 24, 2013
- Arrowhead Research Corporation Announces Proposed Public Offering of Common Stock and WarrantsArrowhead Research Corporation (NASDAQ: ARWR) today announced that it intends to offer units consisting of shares of common stock and warrants in a public offering. Dawson James Securities, ... read more
Thursday, December 20, 2012
- Arrowhead Reports Fiscal 2012 Fourth Quarter and Year-End Financial ResultsArrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2012 fourth quarter and year ended September 30, 2012. ... read more
Tuesday, December 18, 2012
- Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted TherapeuticsArrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it has signed a research collaboration and license agreement with Shire AG, to develop and commercialize ... read more
Friday, December 14, 2012
- Arrowhead to Report Fiscal 2012 Fourth Quarter and Year-End Financial ResultsArrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it will report its financial results for the fiscal 2012 fourth quarter and year ended September ... read more
Friday, December 7, 2012
- Arrowhead Announces Pricing of a Public Offering of Common Stock and WarrantsArrowhead Research Corporation (NASDAQ: ARWR) today announced that it has priced a public offering of approximately 1.8 million units at a price to the public of $2.26 per ... read more
Thursday, December 6, 2012
- Arrowhead Research Corporation Announces Proposed Public Offering of Common Stock and WarrantsArrowhead Research Corporation (NASDAQ: ARWR) today announced that it intends to offer units consisting of shares of common stock and warrants in a public offering. Dawson James Securities, ... read more
Tuesday, November 27, 2012
- Arrowhead Publishes First Ever Cholesterol-siRNA Mediated Gene Knockdown in Primates and Novel DPC Co-Injection StrategyArrowhead Research Corporation (NASDAQ:ARWR), a targeted therapeutics company, today announced the publication of data demonstrating that high level target gene knockdown with low doses of cholesterol-siRNA is ... read more